Previous Close | 51.53 |
1-Year Change | 354.01% |
6-Months Change | -18.22% |
3-Months Change | -19.92% |
Moving Avg (50d) | 64.235 |
Moving Avg (200d) | 62.143 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 5.15B |
Beta (3-Years) | 1.08 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | % |
Return On Assets (ttm) | -21.13% |
EPS (ttm) | -0.93 |
PE Ratio (ttm) | -55.41 |
Dividend Yield | % |
Asset Description: | Viking Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
53.642 | 55.22 | 56.271 | 57.849 | 60.479 | 63.108 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.